Table of Contents
Table of Contents
1 Table Of Contents
1 Table Of Contents 2
1.1 List Of Tables 8
1.2 List Of Figures 10
2 Introduction 11
2.1
What Is This Report About? 11
2.2 Definitions 11
2.2.1 Endoscopy
Devices 11
3 Healthcare Sector Review 13
3.1 Healthcare Expenditure
13
3.2 Healthcare Infrastructure 18
3.2.1 Healthcare Personnel Data
20
3.2.2 Healthcare Facilities Data 23
4 Endoscopy Devices in United
States 25
4.1 Endoscopy Devices Overall Revenues (2000-2012) 25
4.2
Endoscopy Devices Overall Volume (2000-2012) 31
4.3 Endoscopy Devices
Overall Company Shares (2005-2006) 34
4.4 Flexible Endoscope in United
States 35
4.4.1 Flexible Endoscope Overall Revenues (2000-2012) 35
4.4.2 Flexible Endoscope Overall Volume (2000-2012) 37
4.4.3 Flexible
Endoscope Average Price (2000-2012) 39
4.4.4 Flexible Endoscope
Distribution Share (2005-2006) 41
4.4.5 Flexible Endoscope Company Share
(2005-2006) 42
4.5 Rigid Endoscope in United States 43
4.5.1 Rigid
Endoscope Overall Revenues (2000-2012) 43
4.5.2 Rigid Endoscope Overall
Volume (2000-2012) 45
4.5.3 Rigid Endoscope Average Price (2000-2012)
47
4.5.4 Rigid Endoscope Distribution Share (2005-2006) 49
4.5.5 Rigid
Endoscope Company Share (2005-2006) 50
5 OLYMPUS CORPORATION Company
Profile 52
5.1 Company Overview 52
5.2 Business Overview 52
5.2.1
Imaging Systems Business 52
5.2.2 Information and Communication Business
53
5.2.3 Life Sciences Business 53
5.2.4 Medical Systems Business
54
5.2.5 Others 55
5.2.6 Major Products and Services 55
5.2.7
History 56
5.3 Value Chain Analysis 58
5.3.1 Manufacturing 58
5.3.2 Product Development 59
5.3.3 Sales and Marketing 59
5.4 SWOT
Analysis 59
5.4.1 OLYMPUS CORPORATION Strengths 60
5.4.2 OLYMPUS
CORPORATION Weaknesses 61
5.4.3 OLYMPUS CORPORATION Opportunities 61
5.4.4 OLYMPUS CORPORATION Threats 62
5.5 Financial and Operational Review
63
5.5.1 Financial Statements 63
5.5.2 Share Holding Structure 64
5.6 Locations And Subsidiaries 64
5.7 Financial Deals Landscape 66
5.7.1 Spiration Secures $18.5 Million In Series G Round Of Financing 66
5.7.2 Terumo Forms Joint Venture With Olympus Corporation 68
5.7.3 Olympus
Signs An Agreement With Visen Medical 69
5.7.4 Olympus Acquires Stake In
Cytori Therapeutics 70
5.7.5 Olympus Corporation Forms A Joint Venture
With Movaz Networks 72
5.7.6 Spiration Secures $13.4 Million In Series F
Financing 73
5.7.7 Olympus Corporation Forms Partnership With Takano
75
5.7.8 Olympus To Acquire Gyrus Group 76
5.8 Recent Developments
78
5.8.1 Apr 01, 2008: Olympus Appoints New CEO 78
5.8.2 Feb 04, 2008:
Olympus Reports Q3 Fiscal 2008 Results 79
5.8.3 Nov 06, 2007: Olympus
Reports Q2 Fiscal 2008 Results 79
5.8.4 Jul 30, 2007: Olympus Reports Q1
Fiscal 2008 Results 79
5.8.5 Jul 30, 2007: Olympus Reports H1 Fiscal 2006
Results 79
5.8.6 Jul 30, 2007: Olympus Reports Q1 Fiscal 2006 Results
80
5.8.7 Jul 30, 2007: Olympus Reports Fiscal 2006 Results 80
5.8.8
Jul 30, 2007: Olympus Reports Q3 Fiscal 2006 Results 80
5.8.9 Jul 30,
2007: Olympus Reports Q1 Fiscal 2007 Results 80
5.8.10 May 08, 2007:
Olympus Reports Fiscal 2007 Results 80
5.8.11 Feb 05, 2007: Olympus
Reports Q3 Fiscal 2007 Results 80
5.9 OLYMPUS CORPORATION Pipeline
Products 81
5.9.1 OLYMPUS CAPSULE ENDOSCOPE SYSTEM 81
5.9.2 Single
Balloon Enteroscopy (SBE) system 81
6 KARL STORZ GmbH & Co. KG Company
Profile 83
6.1 Company Overview 83
6.2 Business Overview 83
6.2.1
Major Products and Services 83
6.2.2 History 84
6.3 Locations And
Subsidiaries 84
6.4 Financial Deals Landscape 86
6.4.1 KARL STORZ
Signs An Agreement With EndoGastric Solutions 86
7 PENTAX Medical Company
Profile 88
7.1 Company Overview 88
7.2 Business Overview 88
7.2.1
Major Products and Services 89
7.2.2 History 90
7.3 Locations And
Subsidiaries 90
7.3.1 Other Locations & Subsidiaries 91
7.4 Financial
Deals Landscape 92
7.4.1 PENTAX Medical Company Acquires Operating Assets
Of KayPENTAX (formerly Kay Elemetrics) 92
7.5 Recent Developments 93
7.5.1 Oct 06, 2007: PENTAX Appoints VP, Sales And Marketing 93
8 B. Braun
Melsungen AG Company Profile 95
8.1 Company Overview 95
8.2 Business
Overview 95
8.2.1 Aesculap division 95
8.2.2 B. Braun Avitum division
95
8.2.3 Hospital Care division 96
8.2.4 Out Patient Market (OPM)
division 96
8.2.5 Major Products and Services 97
8.2.6 History 97
8.3 Value Chain Analysis 99
8.3.1 Manufacturing 99
8.3.2 Product
Development 100
8.3.3 Sales and Marketing 101
8.4 SWOT Analysis
101
8.4.1 B. Braun Melsungen AG Strengths 101
8.4.2 B. Braun Melsungen
AG Weaknesses 102
8.4.3 B. Braun Melsungen AG Opportunities 103
8.4.4
B. Braun Melsungen AG Threats 103
8.5 Financial and Operational Review
104
8.5.1 Financial Statements 104
8.5.2 Financial Ratios 105
8.6
Locations And Subsidiaries 106
8.7 Financial Deals Landscape 108
8.7.1
B. Braun Signs An Agreement With Nipro 108
8.7.2 B. Braun Enters Into A
Licensing Agreement With Chartie Hospital 109
8.7.3 B. Braun Signs An
Agreement With Charite 110
8.8 Recent Developments 111
8.8.1 Mar 26,
2008: B. Braun Reports 2007 Results 111
8.8.2 Oct 25, 2007: B. Braun
Melsungen Signs Distribution Agreement With NIPRO 113
8.8.3 May 25, 2007:
B. Braun Melsungen Enters Into Strategic Alliance With Health Robotics 114
8.8.4 Mar 28, 2007: B. Braun Melsungen Reports 2006 Results 114
8.8.5 Mar
24, 2007: B. Braun Melsungen To Shut Its Plant In Puerto Rico 115
8.8.6
Mar 15, 2007: B. Braun Melsungen To Invest In Medical Technology Production
115
8.8.7 Sep 19, 2005: B. Braun Medical Opens Manufacturing Facility In
Suzhou 115
8.9 B. Braun Melsungen AG Pipeline Products 116
8.9.1
Coroflex Please 116
8.9.2 SeQuent Please 118
9 Fujinon Corporation
Company Profile 121
9.1 Company Overview 121
9.2 Business Overview
121
9.2.1 Major Products and Services 122
9.2.2 History 122
9.3
Locations And Subsidiaries 124
9.4 Financial Deals Landscape 125
9.4.1
Given Imaging And Fujinon Corporation Sign Global Strategic Collaboration
125
9.5 Recent Developments 126
9.5.1 Jul 11, 2006: Fujinon Reports
Fiscal 2007 Results 126
10 Regulation System 127
10.1 Medical
Equipment Approval Process 127
10.1.1 Pre-market Approval Process 128
10.1.2 Intended use and Indications for use 128
10.1.3 Predicate Device
128
10.1.4 Safe and Effective 129
10.1.5 Other Category Devices
131
10.1.6 Post-Market Approval Process 132
10.1.7 Compliance and
Enforcement 132
10.1.8 Registration Fee 133
10.1.9 Approval Time
133
11 Pricing and Reimbursement 134
11.1 Government Policies 134
11.2 Private Insurance 135
11.3 Diagnosis Related Groups (DRG) 136
12
Distribution Structure 137
12.1 Distribution Structure 137
13 APPENDIX
138
13.1 Methodology 138
13.2 Coverage 139
13.3 Secondary Research
139
13.4 Primary Research 140
13.5 Models 140
13.6 Forecasts
141
13.7 Expert Panels 141
13.8 Currency Conversion 142
13.9
Contact Us 143
13.10 Disclaimer 143
View Cart
